There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Neurocrine (NBIX) and Voyager Therapeutics Inc (VYGR) with bullish sentiments.
Neurocrine (NBIX)
In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Neurocrine, with a price target of $102. The company’s shares closed yesterday at $85.13.
Fein observed:
“Our price target of $102/share is based on an equally weighted composite of: (a) $103/share, as a 35x multiple of taxed and diluted FY25 GAAP EPS of $8.80 discounted back to and (b) an NPV of $101/share (discount rate 10%, growth rate 2%). We base our valuation on a 20% royalty on sales for Elagolix in endometriosis and uterine fibrosis (probability adjusted). For valbenazine, we include the indication of TD. For opicapone, we include the US revenue (63% goes to 85% POS.”
According to TipRanks.com, Fein is a 4-star analyst with an average return of 6.3% and a 44.3% success rate. Fein covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals Inc, DBV Technologies SA – American, and Proteostasis Therapeutics Inc.
Neurocrine has an analyst consensus of Strong Buy, with a price target consensus of $106.57, a 25.2% upside from current levels. In a report released yesterday, Oppenheimer also assigned a Buy rating to the stock with a $105 price target.
See today’s analyst top recommended stocks >>
Voyager Therapeutics Inc (VYGR)
H.C. Wainwright analyst Debjit Chattopadhyay maintained a Buy rating on Voyager Therapeutics Inc today and set a price target of $21. The company’s shares closed yesterday at $11.12, close to its 52-week low of $7.76.
Chattopadhyay commented:
“Valuation: model updates post the Neurocrine collaboration, but no change to our target. Our $21 price target is based on a 13-year DCF analysis primarily focused on VY-AADC in PD, assuming Voyager opts to co-commercializes with 50/50 profit share and also includes probability adjusted development stage milestone payments for the three programs covered under the Neurocrine collaboration agreement. Based on Neurocrine’s commitment of funding the near-to-intermediate term clinical and preclinical costs of the four programs, we are moderating our anticipated R&D expenses beginning in 2019.”
According to TipRanks.com, Chattopadhyay is ranked 0 out of 5 stars with an average return of -8.9% and a 36.5% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Autolus Therapeutics Plc, and Mersana Therapeutics Inc.
Currently, the analyst consensus on Voyager Therapeutics Inc is a Strong Buy with an average price target of $20.43.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
